The tweet was deleted by the author.
But we saved everything 🙂.
Arcutis Biotherapeutics announced the launch of a new topical cream designed to treat atopic dermatitis in children.
This once-daily cream is specifically formulated for young patients aged 2 to 5. The company's latest venture marks a significant milestone in their clinical dermatology pursuits, emphasizing their commitment to addressing common skin conditions in pediatrics. Arcutis Biotherapeutics continues to expand its product portfolio and impact the dermatological treatment landscape.
Arcutis Biotherapeutics’ continued expansion in pediatric dermatology underscores a trajectory previously marked by achievements such as the milestone recognized by Nasdaq. The company’s dedication to growth and innovation, reflected in its latest product launch, builds on strategic directions detailed in its Q3 2025 results and signals ongoing momentum within the competitive biotherapeutic sector.